Company news
Inovio Pharmaceuticals, Inc. news in 2020
Inovio Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
December 23, 2020
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
December 9, 2020
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
December 8, 2020
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
December 6, 2020
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
December 2, 2020
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
November 22, 2020
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
November 15, 2020
INOVIO Reports Third Quarter 2020 Financial Results
November 8, 2020
INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020
October 25, 2020
INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800
September 27, 2020
INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium
September 7, 2020
INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update
August 9, 2020
INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus
July 29, 2020
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
July 28, 2020
INOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020
July 26, 2020
INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
June 29, 2020
INOVIO Expands Senior Management Team
June 24, 2020
INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
June 22, 2020
INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea
June 3, 2020
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
May 19, 2020
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
May 10, 2020
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
April 29, 2020
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
April 27, 2020
INOVIO to Report First Quarter 2020 Financial Results on May 11, 2020
April 26, 2020
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea
April 15, 2020
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
April 14, 2020
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
April 5, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
March 29, 2020
INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia
March 25, 2020
INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
March 11, 2020
Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800
March 2, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
March 1, 2020
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
February 9, 2020
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
January 29, 2020
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
January 22, 2020
Inovio Welcomes Biotech Leader to its Board of Directors
January 14, 2020
Inovio Provides Update on Clinical Program Plans for 2020
January 5, 2020
Decks in 2020
- Investor Day (June 2020)
Investor day · 36 slides · Jun 1, 2020